Brief: Phasebio Pharmaceuticals Inc Voluntarily Ending Its Phase 2B Trial Of Pemziviptadil (Pb1046) In PAH Due To Covid-19 Impacts On Manufacturing

PhaseBio Pharmaceuticals

21/12/2021 13:10

Dec 21 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO PHARMACEUTICALS INC - VOLUNTARILY ENDING ITS
PHASE 2B
TRIAL OF PEMZIVIPTADIL (PB1046) IN PAH DUE TO COVID-19 IMPACTS
ON MANUFACTURING
    * PHASEBIO PHARMACEUTICALS - PHASE 2B TRIAL OF PEMZIVIPTADIL
IN
PAH VOLUNTARILY ENDED EARLY TO EVALUATE EXISTING PROGRAM DATA,
DETERMINE NEXT STEPS FORWARD
    * PHASEBIO PHARMACEUTICALS - TO REPRIORITIZE RESOURCES,
CAPITAL
TOWARDS PRE-COMMERCIALIZATION ACTIVITIES OF BENTRACIMAB &
ADVANCEMENT OF OTHER PIPELINE PROGRAMS

Source text for Eikon:  ID:nBw46jH3Ha 
Further company coverage:  PHAS.O